Why Hims & Hers Health Stock Is Plummeting Today
Hims & Hers will no longer be able to sell generic "compounded" versions, a key driver of its recent success. The U.S. Food and Drug Administration (FDA) removed semaglutide injection products like the blockbuster drugs Ozempic and Wegovy from its shortage list.
Telehealth company Hims & Hers is pushing the boundaries of drug compounding and testing the limits of regulators.
Hims & Hers' acquisition of Trybe Labs broadens its treatment range and enhances its competitive edge through increased data ...
Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...
The ad also marks a pivot for the telehealth company colloquially known as Hims, which rose to prominence just under a decade ago, slickly marketing hair-loss treatments and erectile-dysfunction ...
Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair ...
Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.
Hims and Hers is an online platform that connects patients with licensed healthcare professionals and offers treatments for a range of conditions, including hair loss and sexual wellness ...
The Hims brand has primed people to view both their everyday health and the natural-aging processes as problems that can be ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback